Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.

Sonidegib (Odomzo) for the Systemic Treatment of Adults With Recurrent, Locally Advanced Basal Cell Skin Cancer. P T (2016) 0.81

Metastatic basal cell carcinoma caused by carcinoma misdiagnosed as acne - case report and literature review. Clin Case Rep (2016) 0.78

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74

Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev (2002) 8.56

Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol (2010) 8.55

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med (2009) 8.55

Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science (1996) 8.06

Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell (1996) 7.86

Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature (1998) 7.43

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med (2009) 7.23

Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med (2012) 6.90

Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science (2009) 5.40

Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) (1987) 4.60

A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol (2012) 4.57

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med (2012) 4.19

Basal-cell carcinoma. N Engl J Med (2005) 4.05

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 4.05

The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol (2006) 3.30

Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol (1991) 2.88

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med (2010) 2.86

Use of tanning beds and incidence of skin cancer. J Clin Oncol (2012) 2.65

Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell (2013) 2.62

Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell (2010) 2.54

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Res (2010) 2.45

Indoor tanning and non-melanoma skin cancer: systematic review and meta-analysis. BMJ (2012) 2.43

Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol (2006) 2.35

GDC-0449-a potent inhibitor of the hedgehog pathway. Bioorg Med Chem Lett (2009) 2.17

Nevoid basal cell carcinoma syndrome. Dermatol Clin (1995) 2.12

Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J Invest Dermatol (1998) 2.00

Topical treatment of Basal cell carcinomas in nevoid Basal cell carcinoma syndrome with a smoothened inhibitor. J Invest Dermatol (2011) 1.98

Recurrence rates of treated basal cell carcinomas. Part 3: Surgical excision. J Dermatol Surg Oncol (1992) 1.94

Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol (2005) 1.90

Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol (1984) 1.89

Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer. I. Basal cell carcinoma. Arch Dermatol (1995) 1.87

Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma. J Clin Oncol (2014) 1.86

Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell (2015) 1.73

Mutations in the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res (1997) 1.73

Metastatic basal cell carcinoma. Report of five cases. Cancer (1994) 1.66

Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev (2007) 1.66

Aggressive basal cell carcinoma: presentation, pathogenesis, and management. Cancer Metastasis Rev (2004) 1.58

Regular sunscreen use is a cost-effective approach to skin cancer prevention in subtropical settings. J Invest Dermatol (2009) 1.58

Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature (2007) 1.54

Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient. Dermatol Surg (2012) 1.54

Basal cell carcinomas in a tertiary referral centre: a systematic analysis. Br J Dermatol (2014) 1.46

Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma. Arch Dermatol (2012) 1.36

Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol (2013) 1.35

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res (2014) 1.35

Metastatic basal cell carcinoma: a clinicopathologic study of seventeen cases. Cancer (1980) 1.34

PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene (2001) 1.31

Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther (2012) 1.27

Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clin Cancer Res (2011) 1.25

Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res (2013) 1.25

Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst (1996) 1.17

Recurrence rates of treated basal cell carcinomas. Part 1: Overview. J Dermatol Surg Oncol (1991) 1.12

A dose-response curve for sun exposure and basal cell carcinoma. Int J Cancer (1995) 1.11

Systemic cytotoxic therapy of basal cell carcinoma. A review of the literature. Eur J Cancer (1990) 1.09

Vismodegib. Clin Cancer Res (2012) 1.07

Cyclopamine and related steroidal alkaloid teratogens: their occurrence, structural relationship, and biologic effects. Lipids (1978) 1.06

A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol (2011) 1.06

Risk factors for basal cell carcinoma in the UK: case-control study in 806 patients. J R Soc Med (1997) 1.06

Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol (2013) 1.06

Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer. Cancer Treat Rev (2014) 1.05

Genetic skin diseases predisposing to basal cell carcinoma. Eur J Dermatol (2012) 1.02

HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst (2013) 1.02

UV-specific mutations of the human patched gene in basal cell carcinomas from normal individuals and xeroderma pigmentosum patients. Mutat Res (2000) 0.97

Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg (2012) 0.97

Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol (2006) 0.96

Metastatic basal cell carcinoma: review, pathogenesis, and report of two cases. Arch Dermatol (1977) 0.93

Epidemiology and economic burden of nonmelanoma skin cancer. Facial Plast Surg Clin North Am (2012) 0.92

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib. Cancer Med (2012) 0.92

Giant basal cell carcinoma of the skin: literature review and personal experience. J Eur Acad Dermatol Venereol (2011) 0.91

Platinum-based cytotoxic therapy in basal cell carcinoma--a review of the literature. Acta Oncol (1996) 0.90

Metastatic basal cell carcinoma associated with a small primary tumour. Australas J Dermatol (1985) 0.89

Long-term survival following nodal metastases from basal cell carcinoma. Ann Plast Surg (1990) 0.89

Antitumoral effects of calcitriol in basal cell carcinomas involve inhibition of hedgehog signaling and induction of vitamin D receptor signaling and differentiation. Mol Cancer Ther (2011) 0.88

Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol (1990) 0.87

Incidence, risk factors, and preventative management of skin cancers in organ transplant recipients: a review of single- and multicenter retrospective studies from 2006 to 2010. Dermatol Surg (2012) 0.87

The important role of radiotherapy in patients with non-melanoma skin cancer and other cutaneous entities. J Med Imaging Radiat Oncol (2008) 0.87

Two different scenarios of squamous cell carcinoma within advanced Basal cell carcinomas: cases illustrating the importance of serial biopsy during vismodegib usage. JAMA Dermatol (2014) 0.86

Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer (1985) 0.86

Nonmelanoma skin cancer mortality. A population-based study. Arch Dermatol (1991) 0.86

New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol (2013) 0.86

Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol (2013) 0.85

Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. Arch Pathol Lab Med (2006) 0.85

Multiple highly and moderately differentiated squamous cell carcinomas of the skin during vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol (2014) 0.85

An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma. J Am Acad Dermatol (2014) 0.85

Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest (2006) 0.84

Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma. Oncotarget (2013) 0.83

Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol (2013) 0.83

Responsiveness of metastatic basal-cell carcinoma to chemotherapy. A case report. Cancer (1983) 0.81

Complete response of metastatic basal cell carcinoma to cisplatin chemotherapy: a report on two patients. Arch Dermatol (1990) 0.81

Metastatic basal cell carcinoma: rapid symptomatic response to cisplatin and paclitaxel. ANZ J Surg (2004) 0.81

Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened. ChemMedChem (2013) 0.79

Basal cell carcinoma of the scrotum with lymph node metastasis: report of a case and review of the literature. Int J Dermatol (2005) 0.79

Metastatic basal cell carcinoma: report of a case responding to chemotherapy. Postgrad Med J (1980) 0.79

Molecular basis of basal cell carcinogenesis in the atomic-bomb survivor population: p53 and PTCH gene alterations. Carcinogenesis (2006) 0.79

Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma. J Am Acad Dermatol (2014) 0.79

Recurrence after treatment of cutaneous basal cell and squamous cell carcinomas in patients infected with human immunodeficiency virus. JAMA Dermatol (2013) 0.78

Letter: The incidence of basal cell carcinoma and their metastases in Australia and New Zealand. Australas J Dermatol (1973) 0.78

Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib. J Eur Acad Dermatol Venereol (2014) 0.77

Histologic features predictive of basal cell carcinoma recurrence: results of a multivariate analysis. J Cutan Pathol (1993) 0.77

Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant. Eur J Pharmacol (2013) 0.77